UBX0101
Asset
Senolytic MDM2/p53 interaction inhibitor that induces apoptosis in senescent cells
- Stage
- Phase 2
- Modality
- Small molecule
- Target
- MDM2
- 1
- Indication
- 1
- Trial
- 1
- Developer
Indications
1Knee osteoarthritis
Phase 2, Completed, NCT04129944, clinicaltrials.gov, Oct 17, 2026
In the full profile
- Targets and what it contains3
- Owner and partners1
- Trials1
- Evidence for its targets4
- Competitors5
- Aging relevance1
Every asset’s record: target, stage, trials and the evidence behind it.